Hyperthermic Isolated Limb Perfusion in Locally Advanced Soft Tissue Sarcoma and Progressive Desmoid-Type Fibromatosis with TNF 1 mg and Melphalan (T1-M HILP) Is Safe and Efficient

[1]  L. Mariani,et al.  Desmoid-Type Fibromatosis: A Front-Line Conservative Approach to Select Patients for Surgical Treatment , 2009, Annals of Surgical Oncology.

[2]  O. Merimsky,et al.  Efficacy of high vs low dose TNF-isolated limb perfusion for locally advanced soft tissue sarcoma. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[3]  R. Mirimanoff,et al.  Isolated limb perfusion with tumor necrosis factor and melphalan for non‐resectable soft tissue sarcomas: Long‐term results on efficacy and limb salvage in a selected group of patients , 2008, Journal of surgical oncology.

[4]  P. Kam,et al.  Isolated Limb Infusion for Advanced Soft Tissue Sarcoma of the Extremity , 2008, Annals of Surgical Oncology.

[5]  J. Blay,et al.  High response rates with isolated pelvic perfusion (IPP) with a pneumatic anti-shock garments (PASG) and low-dose TNF-α for locally advanced pelvic sarcomas and carcinomas: A phase II unicenter trial , 2008 .

[6]  J. Blay,et al.  Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[7]  J. Zager,et al.  Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma , 2008, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[8]  H. Hoekstra,et al.  Long-Term Locoregional Vascular Morbidity After Isolated Limb Perfusion and External-Beam Radiotherapy for Soft Tissue Sarcoma of the Extremity , 2007, Annals of Surgical Oncology.

[9]  B. O'Sullivan,et al.  Evidence-based recommendations for local therapy for soft tissue sarcomas. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  B. Seifert,et al.  The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of the Rare Cancer Network , 2007, Radiation oncology.

[11]  D. Fraker,et al.  Tumor Necrosis Factor-alpha Damages Tumor Blood Vessel Integrity by Targeting VE-Cadherin , 2006, Annals of surgery.

[12]  K. Brown,et al.  A Phase II Trial of Isolated Limb Infusion With Melphalan and Dactinomycin for Regional Melanoma and Soft Tissue Sarcoma of the Extremity , 2006, Annals of Surgical Oncology.

[13]  A. Eggermont,et al.  Isolated limb perfusion for melanoma patients—a review of its indications and the role of tumour necrosis factor-α , 2006 .

[14]  A. Eggermont,et al.  Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor‐α and melphalan for limb‐threatening soft tissue sarcoma , 2006 .

[15]  A. Eggermont,et al.  TNF dose reduction in isolated limb perfusion. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[16]  A. Eggermont,et al.  Isolated Limb Perfusions With Tumor Necrosis Factor and Melphalan for Locally Recurrent Soft Tissue Sarcoma in Previously Irradiated Limbs , 2005, Annals of Surgical Oncology.

[17]  F. Cavaliere,et al.  Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha. , 2004, Journal of experimental & clinical cancer research : CR.

[18]  P. Petrow,et al.  MR imaging in the evaluation of isolated limb perfusion: a prospective study of 18 cases , 2004, Skeletal Radiology.

[19]  A. Eggermont.  Isolated limb perfusion in the management of locally advanced extremity soft tissue sarcoma. , 2003, Surgical oncology clinics of North America.

[20]  A. Davis,et al.  Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial , 2002, The Lancet.

[21]  A. Stojadinovic,et al.  Amputation for Recurrent Soft Tissue Sarcoma of the Extremity: Indications and Outcome , 2001, Annals of Surgical Oncology.

[22]  G. Rosen,et al.  Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[24]  O. Merimsky,et al.  Limb desmoid tumors: a possible role for isolated limb perfusion with tumor necrosis factor-alpha and melphalan. , 1999, Surgery.

[25]  A. Eggermont,et al.  Absence of Severe Systemic Toxicity After Leakage-Controlled Isolated Limb Perfusion With Tumor Necrosis Factor-α and Melphalan , 1999, Annals of Surgical Oncology.

[26]  A. Eggermont.  TNF alpha in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectives. , 1998, Anticancer research.

[27]  A. Eggermont,et al.  Isolated limb perfusion in primary and recurrent melanoma: indications and results. , 1998, Seminars in surgical oncology.

[28]  P. Kam,et al.  Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. , 1998, Seminars in surgical oncology.

[29]  W. Molenaar,et al.  Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. , 1998, International journal of radiation oncology, biology, physics.

[30]  W. Molenaar,et al.  Feasibility and Efficacy of External Beam Radiotherapy after Hyperthermic Isolated Limb Perfusion with TNF-α and Melphalan for Limb-saving Treatment in Locally Advanced Extremity Soft-tissue Sarcoma , 1998 .

[31]  R. Keus,et al.  Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha ± interferon gamma and melphalan in patients with irresectable soft tissue tumors , 1997, Journal of surgical oncology.

[32]  M. Inbar,et al.  High dose tumor necrosis factor‐α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation , 1997, Cancer.

[33]  P. Schlag,et al.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.

[34]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[35]  D H Leung,et al.  Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  I. Eisenbarth,et al.  Investigations of neurofibromin expression in the skin of patients with NF 1 (neurofibromatosis type 1) , 1994 .

[37]  P. Kam,et al.  Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. , 1994, Melanoma research.

[38]  G. Sigurdsson,et al.  Anesthesiologists' management of isolated limb perfusion with "high-dose" tumor necrosis factor alpha. , 1993, Anesthesiology.

[39]  A. Stotter.  Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. , 1992, Annals of surgery.

[40]  E. Casper,et al.  The changing role of amputation for soft tissue sarcoma of the extremity in adults. , 1992, Surgery, gynecology & obstetrics.

[41]  J. Kovach,et al.  A phase I clinical trial of recombinant human tumor necrosis factor , 1988, Cancer.

[42]  J. Coindre,et al.  Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system , 1984, International journal of cancer.

[43]  E. V. van Slooten,et al.  Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. , 1982, European journal of cancer & clinical oncology.

[44]  R. F. Ryan,et al.  Chemotherapy of Cancer: Regional Perfusion Utilizing an Extracorporeal Circuit , 1958, Annals of surgery.

[45]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[46]  P. Terrier,et al.  p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-alpha and melphalan. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  C. Beauchamp.  Advanced Extremity Soft Tissue Sarcoma: Prognostic Effect of Isolated Limb Perfusion in a Series of 88 Patients Treated at a Single Institution , 2008 .

[48]  A. V. van Geel,et al.  Isolated limb perfusion for melanoma patients--a review of its indications and the role of tumour necrosis factor-alpha. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[49]  A. Eggermont,et al.  Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. , 2006, Cancer.

[50]  J. Blay,et al.  Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  A. Mittelman,et al.  Phase I clinical trial of recombinant human tumor necrosis factor , 2004, Cancer Chemotherapy and Pharmacology.

[52]  A. Eggermont,et al.  Fifty Tumor Necrosis Factor–Based Isolated Limb Perfusions for Limb Salvage in Patients Older Than 75 Years With Limb-Threatening Soft Tissue Sarcomas and Other Extremity Tumors , 2003, Annals of surgical oncology.

[53]  N. Renard,et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[55]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .

[56]  K. Rothman.  Estimation of confidence limits for the cumulative probability of survival in life table analysis. , 1978, Journal of chronic diseases.